Transcutaneous gene gun delivery of hNC16A induces BPAG2-specific tolerance

Journal of Investigative Dermatology

Volumn 132, Issue 6, 2012, Pages 1665-1671

  Ettinger, Monika ^a   Peckl Schmid, Doris ^a   Gruber, Christina ^a   Laimer, Martin ^a   Thalhamer, Josef ^a   Hintner, Helmut ^b   Gratz, Iris K ^a,c   Bauer, Johann W ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BULLOUS PEMPHIGOID ANTIGEN 2; IMMUNOGLOBULIN G; NC16A ANTIGEN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CELL INFILTRATION; EX VIVO GENE TRANSFER; EX VIVO STUDY; GENE GUN IMMUNIZATION; GRAFT REJECTION; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SKIN GRAFT; T LYMPHOCYTE;

EID: 84861199239     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.19     Document Type: Article

References (6)

1. Condon C, Watkins SC, Celluzzi CM et al. (1996) DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2:1122-8 (Pubitemid 26338632)
2. Ghazizadeh S, Kalish RS, Taichman LB (2003) Immune-mediated loss of transgene expression in skin: Implications for cutaneous gene therapy. Mol Ther 7:296-303 (Pubitemid 36503854)
3. Goudy KS, Wang B, Tisch R (2008) Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice. Clin Immunol 129:49-57
4. Condon C, Watkins SC, Celluzzi CM et al. (1996) DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2:1122-8 (Pubitemid 26338632)
5. Ghazizadeh S, Kalish RS, Taichman LB (2003) Immune-mediated loss of transgene expression in skin: Implications for cutaneous gene therapy. Mol Ther 7:296-303 (Pubitemid 36503854)
6. Goudy KS, Wang B, Tisch R (2008) Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice. Clin Immunol 129:49-57